134 related articles for article (PubMed ID: 19885559)
21. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model.
Martinet O; Ermekova V; Qiao JQ; Sauter B; Mandeli J; Chen L; Chen SH
J Natl Cancer Inst; 2000 Jun; 92(11):931-6. PubMed ID: 10841829
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
24. Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma.
Tsuchiyama T; Nakamoto Y; Sakai Y; Marukawa Y; Kitahara M; Mukaida N; Kaneko S
J Immunol; 2007 Jan; 178(1):574-83. PubMed ID: 17182598
[TBL] [Abstract][Full Text] [Related]
25. Effects of D-Fraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells.
Kodama N; Komuta K; Sakai N; Nanba H
Biol Pharm Bull; 2002 Dec; 25(12):1647-50. PubMed ID: 12499658
[TBL] [Abstract][Full Text] [Related]
26. NK cell depletion diminish tumour-specific B cell responses.
Jensen M; Tawadros S; Sedlacek HH; Schultze JL; Berthold F
Immunol Lett; 2004 May; 93(2-3):205-10. PubMed ID: 15158618
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
28. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement.
Di Carlo E; Comes A; Basso S; De Ambrosis A; Meazza R; Musiani P; Moelling K; Albini A; Ferrini S
J Immunol; 2000 Sep; 165(6):3111-8. PubMed ID: 10975824
[TBL] [Abstract][Full Text] [Related]
29. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12.
Yamanaka R; Tsuchiya N; Yajima N; Honma J; Hasegawa H; Tanaka R; Ramsey J; Blaese RM; Xanthopoulos KG
J Neurosurg; 2003 Oct; 99(4):746-53. PubMed ID: 14567611
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of type I and type III interferons in BNL hepatoma model.
Abushahba W; Balan M; Castaneda I; Yuan Y; Reuhl K; Raveche E; de la Torre A; Lasfar A; Kotenko SV
Cancer Immunol Immunother; 2010 Jul; 59(7):1059-71. PubMed ID: 20217081
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma.
Gao P; Ding Q; Wu Z; Jiang H; Fang Z
Cancer Lett; 2010 Apr; 290(2):157-66. PubMed ID: 19786319
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation.
Ma HI; Hueng DY; Shui HA; Han JM; Wang CH; Lai YH; Cheng SY; Xiao X; Chen MT; Yang YP
Int J Mol Sci; 2014 Mar; 15(3):4393-414. PubMed ID: 24625664
[TBL] [Abstract][Full Text] [Related]
33. Antitumor mechanism of recombinant murine interleukin-12 vaccine.
Yin X; Yan X; Yang Q; Cao H; Liang H
Cancer Biother Radiopharm; 2010 Jun; 25(3):263-8. PubMed ID: 20578831
[TBL] [Abstract][Full Text] [Related]
34. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration.
Orange JS; Wang B; Terhorst C; Biron CA
J Exp Med; 1995 Oct; 182(4):1045-56. PubMed ID: 7561678
[TBL] [Abstract][Full Text] [Related]
35. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells.
Kitajima M; Ito T; Tumes DJ; Endo Y; Onodera A; Hashimoto K; Motohashi S; Yamashita M; Nishimura T; Ziegler SF; Nakayama T
Cancer Res; 2011 Jul; 71(14):4790-8. PubMed ID: 21646476
[TBL] [Abstract][Full Text] [Related]
36. [Human endostatin antiangiogenic gene therapy mediated by recombinant adeno-associated virus vector in nude mouse with endometriosis].
Sun JJ; Yin LR; Mi RR; Ma HD; Guo SJ; Shi Y; Gu YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):45-50. PubMed ID: 20367926
[TBL] [Abstract][Full Text] [Related]
37. Intracranial AAV-IFN-β gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model.
GuhaSarkar D; Neiswender J; Su Q; Gao G; Sena-Esteves M
Mol Oncol; 2017 Feb; 11(2):180-193. PubMed ID: 28098415
[TBL] [Abstract][Full Text] [Related]
38. Impairment of natural killer cytotoxic activity and interferon gamma production in CCAAT/enhancer binding protein gamma-deficient mice.
Kaisho T; Tsutsui H; Tanaka T; Tsujimura T; Takeda K; Kawai T; Yoshida N; Nakanishi K; Akira S
J Exp Med; 1999 Dec; 190(11):1573-82. PubMed ID: 10587348
[TBL] [Abstract][Full Text] [Related]
39. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
